BioLineRx Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLRX research report →
Companywww.biolinerx.com
BioLineRx Ltd. , a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
- CEO
- Philip A. Serlin
- IPO
- 2011
- Employees
- 28
- HQ
- Hevel Modi'in, IL
Price Chart
Valuation
- Market Cap
- $11.97M
- P/E
- -9.74
- P/S
- 9.90
- P/B
- 0.64
- EV/EBITDA
- -5.66
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.07%
- Op Margin
- -874.73%
- Net Margin
- -101.65%
- ROE
- -6.12%
- ROIC
- -30.91%
Growth & Income
- Revenue
- $1.19M · -95.89%
- Net Income
- $-1,184,321 · 87.16%
- EPS
- $-0.29 · -150.65%
- Op Income
- $-10,368,606
- FCF YoY
- 81.42%
Performance & Tape
- 52W High
- $7.77
- 52W Low
- $2.15
- 50D MA
- $2.59
- 200D MA
- $3.18
- Beta
- 0.59
- Avg Volume
- 42.72K
Get TickerSpark's AI analysis on BLRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Yan Shaoyu | other | 0 |
| Oct 5, 16 | PANEM SANDRA | other | 49,800 |
| Oct 5, 17 | PANEM SANDRA | other | 19,800 |
| Oct 5, 18 | PANEM SANDRA | other | 19,800 |
| Oct 2, 19 | PANEM SANDRA | other | 199,800 |
| Oct 2, 20 | PANEM SANDRA | other | 79,800 |
| Oct 2, 21 | PANEM SANDRA | other | 79,800 |
| Oct 3, 24 | PANEM SANDRA | other | 360,000 |
| Oct 3, 23 | PANEM SANDRA | other | 360,000 |
| Jan 1, 25 | PANEM SANDRA | other | 2,055,000 |
Our BLRX Coverage
We haven't published any research on BLRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BLRX Report →